Welcome to our dedicated page for Assembly Bioscie SEC filings (Ticker: ASMB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Assembly Biosciences, Inc. (ASMB) SEC filings provide detailed insight into this clinical-stage biotechnology company’s operations, collaboration agreements and financial position. ASMB’s common stock is registered under Section 12(b) of the Exchange Act and trades on The Nasdaq Global Select Market, so the company submits current reports, registration statements and other documents to the U.S. Securities and Exchange Commission.
On this page, you can review Form 8-K filings in which Assembly Biosciences reports material events. Recent 8-Ks reference press releases announcing quarterly financial results, interim Phase 1b data for ABI-5366 in recurrent genital herpes, and topline Phase 1b results for ABI-4334 in chronic hepatitis B virus infection. Other 8-K filings describe an underwriting agreement for an underwritten, registered offering of common stock, pre-funded warrants and accompanying Class A and Class B warrants, as well as a securities purchase agreement with Gilead Sciences, Inc. for a private placement of common stock and warrants.
These filings outline key terms such as the number and type of securities issued, exercise prices and conditions for warrants, lock-up agreements, net proceeds to the company and intended use of funds for general corporate purposes. They also summarize aspects of the existing investor rights agreement with Gilead and the ownership limitations embedded in the warrants and pre-funded warrants.
For investors analyzing ASMB, the SEC filings complement the company’s press releases by providing formal descriptions of collaboration structures, financing transactions and clinical data disclosures. Stock Titan’s platform surfaces these documents alongside AI-powered summaries that explain the significance of each filing in accessible language, helping readers quickly understand items such as new offerings, private placements, collaboration milestones or clinical study updates.
In addition to 8-Ks, users can access other Assembly Biosciences filings through EDGAR, including annual and quarterly reports that discuss risk factors, collaboration revenue from Gilead, research and development expenses for HSV, HBV and HDV programs, and broader financial statements. Together, these regulatory documents form a primary source for evaluating ASMB’s business progress, capital structure and exposure to clinical and collaboration-related risks.